
    
      A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy
      and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects
      With Persistent Asthma
    
  